Nabriva Therapeutics (NASDAQ:NBRV) Research Coverage Started at

Research analysts at initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRVGet Free Report) in a research note issued on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

NASDAQ NBRV opened at $0.00 on Tuesday. The company has a market cap of $6,403.00, a PE ratio of 0.00 and a beta of 1.53. Nabriva Therapeutics has a 52 week low of $1.22 and a 52 week high of $8.45. The company has a quick ratio of 0.52, a current ratio of 0.85 and a debt-to-equity ratio of 0.12. The firm’s 50-day simple moving average is $0.33 and its two-hundred day simple moving average is $0.83.

Institutional Investors Weigh In On Nabriva Therapeutics

An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC lifted its position in Nabriva Therapeutics plc (NASDAQ:NBRVFree Report) by 102.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 795,938 shares of the biotechnology company’s stock after buying an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned approximately 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent quarter. 0.27% of the stock is currently owned by institutional investors and hedge funds.

Nabriva Therapeutics Company Profile

(Get Free Report)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.

See Also

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with's FREE daily email newsletter.